RT Journal Article
T1 Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.
A1 Milanes-Guisado, Yusnelkis
A1 Gutierrez-Valencia, Alicia
A1 Trujillo-Rodriguez, Maria
A1 Espinosa, Nuria
A1 Viciana, Pompeyo
A1 Lopez-Cortes, Luis Fernando
K1 Anti-HIV Agents
K1 CD4-CD8 Ratio
K1 Cohort Studies
K1 HIV-1
K1 Middle Aged
K1 Sustained Virologic Response
K1 Young Adult
AB To analyse the correlation and concordance between aCD4, CD4%, CD4/CD8, their intra-patient variability, and to compare the immune recovery (IR) rates based on the three parameters in HIV-infected patients after starting antiretroviral therapy. From a prospectively followed cohort, patients who maintained HIV-RNA suppression in ≥95% of the determinations throughout the follow-up were selected. IR was defined as aCD4 >650/μl, CD4% ≥38% or CD4/CD8 ≥1. A total of 1164 patients with a median follow-up of 5 years were analysed. The increases in aCD4, CD4% and CD4/CD8 were highest during the first year and considerably lower thereafter regardless of baseline aCD4. The annual increases in aCD4 showed poor correlations with those of CD4% (r = 0.143-0.250) and CD4/CD8 (r = 0.101-0.192) but were high between CD4% and CD4/CD8 (r = 0.765-0.844; p650/μl, CD4% ≥38%, and CD4/CD8 ≥1, respectively, while only 31% achieved both aCD4 and CD4/CD8 target values. The increases in aCD4 poorly correlate with those of CD4% and CD4/CD8. IR rates based on aCD4 significantly overstate those obtained by CD4% and CD4/CD8. CD4% and CD4/CD8 are more stable markers than aCD4 and should be taken into account to monitor the IR after treatment initiation.
PB Public Library of Science
YR 2018
FD 2018-10-22
LK http://hdl.handle.net/10668/13116
UL http://hdl.handle.net/10668/13116
LA en
NO Milanés-Guisado Y, Gutiérrez-Valencia A, Trujillo-Rodríguez M, Espinosa N, Viciana P, López-Cortés LF. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. PLoS One. 2018 Oct 22;13(10):e0205777.
DS RISalud
RD Apr 9, 2025